169 related articles for article (PubMed ID: 17261816)
1. Our moral obligations in caring for patients with orphan cancers.
Fernandez CV
CMAJ; 2007 Jan; 176(3):297, 299. PubMed ID: 17261816
[No Abstract] [Full Text] [Related]
2. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
3. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
4. Ethical considerations in orphan drug approval and use.
Kesselheim AS
Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660
[TBL] [Abstract][Full Text] [Related]
5. Rare diseases, orphan drugs, and orphaned patients.
Scheindlin S
Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
[No Abstract] [Full Text] [Related]
6. Rare opportunities appear on the horizon to treat rare diseases.
Torres C
Nat Med; 2010 Mar; 16(3):241. PubMed ID: 20208483
[No Abstract] [Full Text] [Related]
7. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
8. Adopting orphan drugs--two dozen years of treating rare diseases.
Haffner ME
N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
[No Abstract] [Full Text] [Related]
9. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
Herder M
Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
[TBL] [Abstract][Full Text] [Related]
10. Ethical dilemmas about orphan drugs for orphan diseases.
Isaacs D
J Paediatr Child Health; 2014 Apr; 50(4):249-50. PubMed ID: 24698059
[No Abstract] [Full Text] [Related]
11. Orphan economics: the downside of supplyside pharmacology.
Samson K
Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
[No Abstract] [Full Text] [Related]
12. Should off-label drug use be off-the-table?
Rivkees SA
J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
[No Abstract] [Full Text] [Related]
13. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
14. EU to review rare disease drugs market exclusivity.
Sheridan C
Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
[No Abstract] [Full Text] [Related]
15. The routes to orphan drug designation--our recent experience at the FDA.
Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA
Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120
[No Abstract] [Full Text] [Related]
16. Jumpstarting research into neglected diseases.
Leslie M
Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
[TBL] [Abstract][Full Text] [Related]
17. An Orphan Drug Framework (ODF) for Canada.
Lee DK; Wong B
J Popul Ther Clin Pharmacol; 2014; 21(1):e42-6. PubMed ID: 24671833
[TBL] [Abstract][Full Text] [Related]
18. Policymaking for Orphan Drugs and Its Challenges.
Rhee TG
AMA J Ethics; 2015 Aug; 17(8):776-9. PubMed ID: 26270879
[No Abstract] [Full Text] [Related]
19. [Distribution of orphan drugs by the pharmacist of the Faculty of Veterinary Medicine].
Tijdschr Diergeneeskd; 2004 Jul 15-Aug 1; 129(14-15):486. PubMed ID: 15344826
[No Abstract] [Full Text] [Related]
20. Law and research could add up to profitable niche drugs.
Haefner B
Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
[No Abstract] [Full Text] [Related]
[Next] [New Search]
